160 related articles for article (PubMed ID: 31961477)
1. Early Adalimumab and Anti-Adalimumab Antibody Levels for Prediction of Primary Nonresponse in Ankylosing Spondylitis Patients.
Ding X; Zhu R; Wu J; Xue L; Gu M; Miao L
Clin Transl Sci; 2020 May; 13(3):547-554. PubMed ID: 31961477
[TBL] [Abstract][Full Text] [Related]
2. An examination of the mechanisms involved in secondary clinical failure to adalimumab or etanercept in inflammatory arthropathies.
Bandrés Ciga S; Salvatierra J; López-Sidro M; García-Sánchez A; Durán R; Vives F; Raya-Álvarez E
J Clin Rheumatol; 2015 Apr; 21(3):115-9. PubMed ID: 25807089
[TBL] [Abstract][Full Text] [Related]
3. Frequency of peripheral diseases in Korean patients with ankylosing spondylitis and the effectiveness of adalimumab.
Lee SH; Park W; Won Lee S; Kim HA; Choe JY; Lee SH; Lee SS; Park SH; Park MC; Sheen DH; Lee HS; Lee YA; Lee Y; Kim TH
Int J Rheum Dis; 2020 Aug; 23(9):1175-1183. PubMed ID: 32725789
[TBL] [Abstract][Full Text] [Related]
4. Significance of measurement of serum trough level and anti-drug antibody of adalimumab as personalised pharmacokinetics in patients with Crohn's disease: a subanalysis of the DIAMOND trial.
Nakase H; Motoya S; Matsumoto T; Watanabe K; Hisamatsu T; Yoshimura N; Ishida T; Kato S; Nakagawa T; Esaki M; Nagahori M; Matsui T; Naito Y; Kanai T; Suzuki Y; Nojima M; Watanabe M; Hibi T;
Aliment Pharmacol Ther; 2017 Nov; 46(9):873-882. PubMed ID: 28884856
[TBL] [Abstract][Full Text] [Related]
5. Search for a concentration-effect curve of adalimumab in ankylosing spondylitis patients.
Marsman AF; Kneepkens EL; Ruwaard J; Wei JC; Nurmohamed MT; van Denderen C; van der Horst-Bruinsma IE; Rispens T; Wolbink G
Scand J Rheumatol; 2016 Jul; 45(4):331-4. PubMed ID: 26727457
[No Abstract] [Full Text] [Related]
6. The clinical relevance of early anti-adalimumab antibodies detection in rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: A prospective multicentre study.
Hoxha A; Calligaro A; Tonello M; Ramonda R; Carletto A; Paolazzi G; Bortolotti R; Del Ross T; Grava C; Boaretto M; Favaro M; Teghil V; Ruffatti A; Punzi L
Joint Bone Spine; 2016 Mar; 83(2):167-71. PubMed ID: 26750762
[TBL] [Abstract][Full Text] [Related]
7. Persistence of Infliximab in Circulation for 7 Years?
Kelting SM; Kimpel DL; Bruns DE
Clin Chem; 2015 Nov; 61(11):1420-1. PubMed ID: 26511353
[No Abstract] [Full Text] [Related]
8. Predictive factors for partial remission according to the Ankylosing Spondylitis Assessment Study working group in patients with ankylosing spondylitis treated with anti-TNFα drugs.
Perrotta FM; Addimanda O; Ramonda R; D'Angelo S; Lubrano E; Marchesoni A; Olivieri I; Punzi L; Salvarani C; Spadaro A
Reumatismo; 2014 Nov; 66(3):208-14. PubMed ID: 25376955
[TBL] [Abstract][Full Text] [Related]
9. Proactive Monitoring of Adalimumab Trough Concentration Associated With Increased Clinical Remission in Children With Crohn's Disease Compared With Reactive Monitoring.
Assa A; Matar M; Turner D; Broide E; Weiss B; Ledder O; Guz-Mark A; Rinawi F; Cohen S; Topf-Olivestone C; Shaoul R; Yerushalmi B; Shamir R
Gastroenterology; 2019 Oct; 157(4):985-996.e2. PubMed ID: 31194979
[TBL] [Abstract][Full Text] [Related]
10. Adalimumab serum levels and antidrug antibodies towards adalimumab in peripheral spondyloarthritis: no association with clinical response to treatment or with disease relapse upon treatment discontinuation.
Paramarta JE; Baeten DL
Arthritis Res Ther; 2014 Jul; 16(4):R160. PubMed ID: 25074046
[TBL] [Abstract][Full Text] [Related]
11. Early drug and anti-infliximab antibody levels for prediction of primary nonresponse to infliximab therapy.
Bar-Yoseph H; Levhar N; Selinger L; Manor U; Yavzori M; Picard O; Fudim E; Kopylov U; Eliakim R; Ben-Horin S; Chowers Y; Ungar B
Aliment Pharmacol Ther; 2018 Jan; 47(2):212-218. PubMed ID: 29124774
[TBL] [Abstract][Full Text] [Related]
12. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
McLeod C; Bagust A; Boland A; Dagenais P; Dickson R; Dundar Y; Hill RA; Jones A; Mujica Mota R; Walley T
Health Technol Assess; 2007 Aug; 11(28):1-158, iii-iv. PubMed ID: 17651658
[TBL] [Abstract][Full Text] [Related]
13. Adalimumab Therapy Restores the Gut Microbiota in Patients With Ankylosing Spondylitis.
Chen Z; Zheng X; Wu X; Wu J; Li X; Wei Q; Zhang X; Fang L; Jin O; Gu J
Front Immunol; 2021; 12():700570. PubMed ID: 34539629
[TBL] [Abstract][Full Text] [Related]
14. Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: a multicenter, randomized, double-blind, placebo-controlled study.
Lambert RG; Salonen D; Rahman P; Inman RD; Wong RL; Einstein SG; Thomson GT; Beaulieu A; Choquette D; Maksymowych WP
Arthritis Rheum; 2007 Dec; 56(12):4005-14. PubMed ID: 18050198
[TBL] [Abstract][Full Text] [Related]
15. Comparison of drug survival and clinical outcome in patients with ankylosing spondylitis treated with etanercept or adalimumab.
Ruwaard J; l'Ami MJ; Marsman AF; Kneepkens EL; van Denderen JC; van der Horst-Bruinsma IE; Nurmohamed MT; Wolbink G
Scand J Rheumatol; 2018 Mar; 47(2):122-126. PubMed ID: 28745108
[TBL] [Abstract][Full Text] [Related]
16. An explorative study on deep profiling of peripheral leukocytes to identify predictors for responsiveness to anti-tumour necrosis factor alpha therapies in ankylosing spondylitis: natural killer cells in focus.
Schulte-Wrede U; Sörensen T; Grün JR; Häupl T; Hirseland H; Steinbrich-Zöllner M; Wu P; Radbruch A; Poddubnyy D; Sieper J; Syrbe U; Grützkau A
Arthritis Res Ther; 2018 Aug; 20(1):191. PubMed ID: 30157966
[TBL] [Abstract][Full Text] [Related]
17. Anti-TROVE2 Antibody Determined by Immune-Related Array May Serve as a Predictive Marker for Adalimumab Immunogenicity and Effectiveness in RA.
Chen PK; Lan JL; Chen YM; Chen HH; Chang SH; Chung CM; Rutt NH; Tan TM; Mamat RNR; Anuar ND; Blackburn JM; Chen DY
J Immunol Res; 2021; 2021():6656121. PubMed ID: 33763493
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of adalimumab in Chinese adults with active ankylosing spondylitis: results of a randomised, controlled trial.
Huang F; Gu J; Zhu P; Bao C; Xu J; Xu H; Wu H; Wang G; Shi Q; Andhivarothai N; Anderson J; Pangan AL
Ann Rheum Dis; 2014 Mar; 73(3):587-94. PubMed ID: 23475983
[TBL] [Abstract][Full Text] [Related]
19. Transaminase elevation secondary to the use of adalimumab.
Juan-Guardela ML; Marín-Carrillo LF; Kattah-Martínez LX; Fernández-Ávila DG
Reumatol Clin; 2014; 10(4):265-6. PubMed ID: 24485042
[No Abstract] [Full Text] [Related]
20. Efficiency of adalimumab, etanercept and infliximab in ankylosing spondylitis in clinical practice.
Escudero-Vilaplana V; Ramírez-Herráiz E; Alañón-Plaza E; Trovato-López N; García-Vicuña R; Carreño-Pérez L; Morell-Baladrón A; Sanjurjo-Sáez M
Int J Clin Pharm; 2015 Oct; 37(5):808-14. PubMed ID: 25910480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
